GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Nicolai Portelli named CEO of Charles de Giorgio Ltd
He brings extensive management experience, having held senior positions across many industries.
Lawrence Schembri approved as BOV Chief People Officer
Lawrence Schembri's appointment has received regulatory approval.
Matt Vella launches QR service to help people contact owners of parked cars
Vive is meant to facilitate situations such as when a parked vehicle is blocking another car.
Port Gillieru opens a new chapter in Malta’s corporate festive celebrations
Port Gillieru is establishing itself as a new destination for corporate events in Malta.
